Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$114.70
neg -0.17
-0.15%
Today's Range: 114.41 - 115.10 | JNJ Avg Daily Volume: 7,251,000
Last Update: 01/18/17 - 4:03 PM EST
Volume: 5,008,346
YTD Performance: -0.30%
Open: $114.97
Previous Close: $114.87
52 Week Range: $94.28 - $126.07
Oustanding Shares: 2,720,531,728
Market Cap: 311,772,936,029
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 8 8 8
Moderate Buy 2 2 2 2
Hold 9 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.26 2.16 2.16 2.11
Latest Dividend: 0.80
Latest Dividend Yield: 2.79%
Dividend Ex-Date: 02/24/17
Price Earnings Ratio: 20.11
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
20.11 20.30 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.06% 18.42% 20.84%
GROWTH 12 Mo 3 Yr CAGR
Revenue -5.70 0.00 0.01
Net Income -5.60 0.50 0.13
EPS -3.90 0.40 0.12
Earnings for JNJ:
EBITDA 22.04B
Revenue 70.07B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $1.56 $1.76 $6.71 $7.07
Number of Analysts 12 6 12 13
High Estimate $1.62 $1.80 $6.75 $7.25
Low Estimate $1.54 $1.67 $6.69 $6.83
Prior Year $1.44 $1.68 $6.20 $6.71
Growth Rate (Year over Year) 7.99% 4.66% 8.16% 5.47%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
After an up-and-down year, this household name is as strong as ever.
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
Animal health and oncology deal activity is heating up in 2017.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Disney and Goldman are doing a lot of the heavy lifting.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.
The Fed seems to have aligned itself with the new emerging themes of financials and small-caps.

Columnist Conversations

Speculators of all sizes are holding the largest bearish position in 10-year notes that we've seen in years. ...
Market is meandering on what is kind of nothing day trading wise with the major indices largely flat lined. &n...
FIBOCALL: The MORNING FIBOCALL for 1/18/17 The SPX-cash trading below the 20 DMA yesterday, but closed above....
Shares of PG area trading at new January highs this afternoon.  The stock is up over 1.75% and has been m...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.